News Quantified

RCKT – rocket pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Rocket Pharmaceuticals (RCKT) was downgraded by Wall Street Zen from

Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances [Yahoo! Finance]

Rocket Pharmaceuticals (RCKT) had its price target raised by The Goldman Sachs Group, Inc. from $2.00 to $3.00. They now have a "sell" rating on the stock.

Rocket Pharmaceuticals (RCKT) was upgraded by Lifesci Capital to "strong-buy".

RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus [Yahoo! Finance]

10.6%

BEAT

-1.9%

BEAT

-7.4%

MISS

-0.7%

BEAT

Cantor Fitzgerald

Form EFFECT ROCKET PHARMACEUTICALS,

Form 8-K ROCKET PHARMACEUTICALS, For: Mar 10

Form 424B5 ROCKET PHARMACEUTICALS,

Form S-3 ROCKET PHARMACEUTICALS,

Form 8-K ROCKET PHARMACEUTICALS, For: Feb 26

Top News Gainers

3/19 Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease 32.9%

12/6 Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia 12.8%

9/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 12.7%

10/15 Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress 8.2%

12/13 Rocket Pharmaceuticals Announces Closing of Public Offering 7.3%

9/6 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 6.5%

4/2 Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day 6.5%

9/10 Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine 6.0%

9/4 Form 4 ROCKET PHARMACEUTICALS, For: Sep 02 Filed by: Militello John 5.8%

2/11 Form 8-K ROCKET PHARMACEUTICALS, For: Feb 10 5.2%

Top News Decliners

3/12 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock. -20.5%

12/10 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock -14.0%

3/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -12.4%

3/26 Form 4 ROCKET PHARMACEUTICALS, For: Mar 24 Filed by: Shah Gaurav -9.5%

3/6 Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 -7.8%

3/17 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.9%

5/22 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.2%

9/26 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is now covered by analysts at Piper Jaffray Companies. They set an "overweight" rating on the stock. -4.9%

4/1 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.7%

3/5 Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day